BioNTech’s Gotistobart Nearly Doubles Survival in Squamous NSCLC Trial
Event summary
- Gotistobart demonstrated a median overall survival of 18.5 months vs. 10.0 months with standard-of-care chemotherapy in squamous NSCLC patients.
- The Phase 3 PRESERVE-003 trial’s non-pivotal stage 1 data showed a statistically significant OS benefit (HR: 0.56; p=0.0295).
- Gotistobart’s safety profile was manageable, with 44.4% of patients experiencing grade ≥3 treatment-related adverse events.
- The pivotal stage 2 of the PRESERVE-003 trial is ongoing at over 160 global sites.
The big picture
BioNTech’s gotistobart represents a potential paradigm shift in treating squamous NSCLC, a disease with limited second-line options and a median survival of less than a year. The Phase 3 trial results position gotistobart as a leading immunotherapy candidate, leveraging a differentiated mechanism of action to selectively deplete regulatory T cells in the tumor microenvironment. If confirmed in the pivotal stage, these findings could redefine the treatment landscape for a patient population in urgent need of new therapies.
What we're watching
- Regulatory Pathway
- Whether the FDA and NMPA will expedite approvals given the Breakthrough Therapy and Fast Track designations.
- Commercial Potential
- The pace at which BioNTech and OncoC4 can scale manufacturing and commercialization if gotistobart gains approval.
- Competitive Landscape
- How existing and emerging therapies for squamous NSCLC will respond to gotistobart’s clinical data.
Related topics